New integration platform leverages a library of predefined connectors and allows clients to write their own custom connectors, easing the pain of creating and managing system integrations.
IRVINE, Calif.-June 14, 2006-DataLabs, an innovative developer of Internet-based software applications for clinical development, today announced the release of DataLabs Connect™ v2.0. DataLabs Connect is an enterprise-level middleware product built specifically for the biopharmaceutical industry. A first for the industry, DataLabs Connect includes an application server, management portal, connector framework and predefined connectors that integrate the entire suite of DataLabs' products including Galt Associates dsNavigator encoding and dictionary management product and other best-of-breed products.
DataLabs will be at booth #1829 at the DIA Annual Conference
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.